FIGURE 1 Cumulative incidence rates (CIRs) for CIN2+ and CIN3+ during 2 years of follow-up by baseline AHPV-GT status, age at diagnosis and enrolment cytology status. CIN, cervical intraepithelial neoplasia; AHPV-GT+, Aptima HPV 16 18/45 genotype assay positive; AHPV-GT–, AHPV E6/E7 mRNA assay positive other than 16 and 18/45; NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion.